Discussion
breast cancer
BREAST CANCER
This is the first study worldwide, analyzing the effect of neoadjuvant denosumab on breast cancer DTCs. Overall DTC-positivity in our study cohort (25.7%) was comparable to that reported in a comprehensive meta-analysis of 4703 patients with stage I-III breast cancer (30.6%) [The fact that (1) anti-resorptive therapy with bisphosphonates is already known to eradicate DTCs in the BM [We report for the overall cohort that (1) DTC-positivity at baseline is non-predictive for response to NACT and that (2) DTC-eradication does not parallel the pCR rate. These finding are supported by a previous study to show that there is no overall association between pCR and DTC-status after NACT [The underlying GeparX trial showed that the addition of denosumab to NACT did not increase pCR [